by BERNAMA/ graphic by MZUKRI

RESPONDING to the ongoing global COVID-19 pandemic, PRA Health Sciences is expanding its industry-leading Mobile Health Platform for remote clinical monitoring, adding several new capabilities that address sponsor needs for COVID-19 virtual study support.

PRA’s Mobile Health Platform (MHP) engages with patients wherever they are. The app-based platform allows sponsors to do everything that’s possible in a physician’s office or clinical site, virtually.

The new capabilities added to address COVID-19 are designed to support clinical trial sponsors and sites participating in clinical studies by allowing them to connect and coordinate with patients who are no longer able to travel to sites due to the current pandemic.

In addition, the mobile app can also be deployed to transition existing traditional, paper-based studies into more decentralised, siteless studies so that medical care and the evaluation of patients can continue during critical study time-frames.

The mobile app features an administrative web app for investigators and sites, and a downloadable mobile app for patients.

It also has the ability to gather electronic informed consent and e-signatures, and complete patient reported outcomes. Using connected devices, the app can also collect home healthcare data and serve into the source for the clinical trial.

PRA’s MHP is built with each specific trial in mind and can be rapidly deployed in as little as one week or less. More details at https://prahs.com/pra-mobile-health-platform.